Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Merck Stock Rises Despite 73rd Rank in Trading Volume

Market BriefMonday, May 19, 2025 8:12 pm ET

1min read

On May 19, 2025, Merck & Co Inc (MRK) saw a trading volume of $896 million, marking a 21.21% decrease from the previous day. The stock ranked 73rd in terms of trading volume for the day. MRK's stock price rose by 1.54%, marking the third consecutive day of gains, with a total increase of 5.12% over the past three days.

Merck has initiated the IDeate-Esophageal01 Phase 3 trial for ifinatamab deruxtecan, a potential first-in-class B7-H3 directed antibody drug conjugate. This trial aims to evaluate the efficacy and safety of the drug against chemotherapy in certain patients with pretreated advanced or metastatic esophageal squamous cell carcinoma.

In addition to the esophageal cancer trial, Merck has also launched the waveLINE-010 Phase 3 clinical trial in February 2025. This trial is part of Merck's expanding phase III pipeline, which has nearly tripled since 2021. The company's pipeline growth is supported by both in-house progress and the addition of candidates through mergers and acquisitions.

Merck's stock has received a Buy rating and a price target of $105.00 from UBS, as the company anticipates results from its ongoing clinical trials. The positive outlook from UBS, coupled with Merck's expanding pipeline, has contributed to the recent upward trend in the stock price.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.